Ai-Biopharma

Executive Summary

Ai-Biopharma is a French AI-driven biopharmaceutical company founded in 2019 that leverages machine learning and computational chemistry to accelerate drug discovery. The company offers in-silico services including chemoinformatics, molecular modeling, and data analysis, while also developing its own internal preclinical pipeline focused on viral diseases, particularly Hepatitis B. Operating at the intersection of artificial intelligence and virology, Ai-Biopharma aims to reduce the time and cost of identifying novel drug candidates through its proprietary AI platform. As a private, pre-clinical stage company with no disclosed funding or valuation, Ai-Biopharma represents an early-stage opportunity in the rapidly growing AI-drug discovery space. The company's dual revenue model—services and internal pipeline—provides near-term cash flow while building long-term value. However, the lack of publicly disclosed pipeline candidates or partnerships underscores its early developmental stage. Key risks include the competitive landscape of AI biotech, regulatory hurdles, and the need for substantial capital to advance candidates into clinical trials. Despite these challenges, the company's focus on Hepatitis B, an area with high unmet medical need, and its AI-driven approach position it as a potentially interesting player in the precision drug discovery arena. Near-term catalysts could include lead optimization results, service contract wins, or strategic collaborations.

Upcoming Catalysts (preview)

• Q2 2026Announcement of lead optimization data for Hepatitis B candidate30% success
• Q3 2026New service contract with major pharma or biotech40% success
• Q4 2026Series A funding round or government grant35% success